Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Computing
Conference & Expo
November 2-4, 2009 NYC
Register Today and SAVE !..

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
In many cases, the end of the year gives you time to step back and take stock of the last 12 months. This is when many of us take a hard look at what worked and what did not, complete performance reviews, and formulate plans for the coming year. For me, it is all of those things plus a time when I u...
SYS-CON.TV
Avita Medical Initiates European Trial Using ReCell in the Management of Chronic Lower Limb Ulcers

NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM -- (Marketwire) -- 11/20/12 --


  • UP TO FIVE EUROPEAN CENTERS TO PARTICIPATE
  • PRELIMINARY STUDIES IN TREATMENT OF VENOUS LEG ULCERS YIELD POSITIVE RESULTS: DEMONSTRATE ACCELERATED HEALING AND REDUCED PAIN AS COMPARED WITH CURRENT STANDARD OF CARE
  • SUBSTANTIAL MARKET; US ANNUAL LOWER LIMB ULCER TREATMENT COSTS $25 BILLION

Regenerative medicine company Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY) has initiated a multicenter randomized control study on the use of ReCell® Spray-On Skin® in the treatment of venous leg ulcers. Up to five European centers from countries including the United Kingdom, Germany, France and Denmark will participate in the study.

Lower limb ulcers (LLUs), which include venous leg ulcers and diabetic foot ulcers, are a major healthcare problem in developed countries due to their prevalence, high cost of treatment and significant impact on patient quality of life. LLUs afflict nearly 1.5% of the general population in OECD countries and up to 3% over the age of 70 years. The expense of treating LLUs imposes a major financial burden on healthcare systems. In the US alone some 6.5 million people suffer from LLUs with associated treatment costs estimated in excess of US$25 billion per annum with similar prevalence and expense documented in the UK, Germany and France. The costs to patients include associated morbidity, pain, lack of mobility and lost work days and wages.

In preliminary open-label studies ReCell was used at four European centers to treat approximately 80 patients suffering from venous leg ulcers and diabetic foot ulcers. Across study centers patients' average age was approximately 70 years, wounds were open an average of approximately 13 months and averaged approximately 21 cm2 in size.

Results of these preliminary studies have been encouraging. Over 70% of patients showed complete healing of the wound within 7-12 weeks following a single treatment with ReCell. With the current standard of care treatment it would be expected that approximately 43% of these wounds would have achieved closure during this period, thus ReCell appears to yield a highly significant positive effect on wound healing. Pain, a critical indicator of quality of life, was reported as being significantly reduced or eliminated within 72 hours following the ReCell treatment.

These data have been presented at congresses and have been submitted as separate papers for publication in peer-reviewed journals.

Given the positive results achieved in preliminary studies, Avita has initiated a randomized control study with leading clinicians at up to 5 European centers. Up to 80 patients will be enrolled in the study. Study protocols have been submitted for approval by the relevant ethics review boards at each center. It is anticipated that enrolment in the study will commence during the 1st quarter of 2013.

Dr. William Dolphin, CEO of Avita Medical, said, "The early results achieved in the treatment of chronic ulcers with ReCell are highly promising. These are hard-to-heal ulcers that pose an enormous burden on healthcare systems and seriously impact on patient's quality of life.

"ReCell is approved for use in Europe, Australia and other markets with over 4500 procedures conducted to date, mainly for burns. Improved leg ulcer treatment will provide tremendous relief for ulcer patients, potentially deliver significant cost savings to financially stressed healthcare systems and may open additional very large markets for ReCell."

ABOUT AVITA MEDICAL LTD.
Avita Medical (http://www.avitamedical.com/) develops and distributes regenerative and tissue-engineered products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary tissue-culture, collection and application technology provides innovative treatment solutions derived from a patient's own skin. The company's lead product, ReCell® Spray-On Skin™, is used in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA-registered in Australia, and SFDA-cleared in China. ReCell is not available for sale in the United States; in the US ReCell is an investigational device limited by federal law to investigational use. An FDA trial on the safety and efficacy of ReCell is in process.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2159670

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:
Avita Medical Ltd.
Stella Sung, Ph.D.
Business Development Officer
Phone:+1 818-356-9400
Email: ssung@avitamedical.com

Investor Relations:
ProActive Capital Resources Group, LLC
Jeff Ramson
CEO
641 Lexington Avenue, 6th Floor
New York, NY. 10022
Phone:+1 646-863-6893
Email: jramson@proactivecapitalgroup.com

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

SOA World Latest Stories
With the capability to reduce both CapEx and OpEx, it’s easy to see why the SDN-NFV trend has taken hold in the hosting and mobile industry. Early use cases include network virtualization from cloud service providers and enterprise data centers, bandwidth calendaring and network tappin...
In this challenging environment, a combination of automated integration testing and test virtualization can enable test teams to improve software quality and keep up with the rate of change. This white paper helps address these needs by describing the benefits that can be gained throug...
The Domain Name Service (DNS) is one of the most important components in networking infrastructure, enabling users and services to access applications by translating URLs (names) into IP addresses (numbers). Because every icon and URL and all embedded content on a website requires a DN...
The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long development cycles that produce software that is ob...
Cloudian on Tuesday announced immediate availability of Cloudian HyperStore appliances and Cloudian HyperStore 5.0 software. Flash-optimized, rack-ready HyperStore appliances make it easy to economically deploy full-featured, highly scalable S3-compliant storage with three enterprise-f...
WaveMaker on Tuesday announced WaveMaker Enterprise, licensed software that enables organizations to run their own end-to-end application platform as a service (aPaaS) for building and running custom apps. WaveMaker Enterprise is a commercially available rapid API app development and d...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021


SYS-CON Featured Whitepapers
ADS BY GOOGLE